Teijin and Nakashima Holdings are joining forces to try to claim a bigger share of the Japanese medical device market. Teijin is acquiring half of Nakashima Medical, a subsidiary of Nakashima Holdings, for about ¥1.5 billion ($12.6 million) as of April 1.
In mid-January, Johnson & Johnson asked the district judge overseeing the federal lawsuit over the transvaginal mesh devices from its Ethicon subsidiary to investigate phone calls urging women with the implant to file suit against the company. But now it's requesting to withdraw that motion.
Industry players are scrambling to differentiate their implantable cardioverter defibrillators that deliver electric shocks to correct abnormal heart rhythms in patients with ventricular tachycardia or fibrillation. Medtronic has touted studies showing that its devices produce fewer unnecessary shocks than the industry norm and are easy to program. Today, it's Boston Scientific's turn.
Johnson & Johnson asked the district judge overseeing the federal lawsuit against its vaginal mesh devices to investigate phone calls urging women with the implant to file suit against the company.
HeartWare announced the first implant of its HeartWare Ventricular Assist System and HVAD Pump using the less-invasive thoracotomy procedure in patients with its HVAD Lateral clinical trial of end-stage heart failure patients who are waiting for a heart transplant.
Weeks after a federal judge encouraged C.R. Bard to resolve thousands of pending lawsuits over its vaginal mesh implants, the company is requesting a delay of its product liability trial, arguing that the judge's comments regarding a potential settlement may have prejudiced the jury pool.
GlySens will use a $12 million Series C financing to conduct a clinical trial for a second iteration of its receiver and implantable sensor that enable continuous glucose monitoring for diabetic patients.
Catheter-based peripheral artery disease treatment company Avinger filed with the SEC to raise up to $69 million, while molecular diagnostics player HTG Molecular Diagnostics filed to raise up to $60 million. In addition, orthopedic regenerative medicine player CollPlant is reportedly seeking a listing on a U.S. market; it is already listed publicly in Israel.
A U.S. federal appeals court cut the patent infringement damages that Zimmer must pay to Stryker from $228 million to $70 million, overruling a previous decision that found the infringement was willful.
Chicago-based private equity group First Analysis expects its $12 million cash infusion into Sonoma Orthopedic Products will be sufficient for the startup to gain FDA clearance for a new ankle implant--as well as to launch it and start to scale up sales.